Temple’s Arthur Feldman, MD, PhD, Elected to The Johns Hopkins Society of Scholars
Arthur M. Feldman, MD, PhD, Executive Dean of Temple University School of Medicine, was elected to membership in the prestigious Johns Hopkins Society of Scholars. The Society, established nearly 50 years ago by the Trustees of the University, honors distinguished former Johns Hopkins postdoctoral fellows and junior or visiting faculty who served at least a year at Hopkins and thereafter gained marked distinction elsewhere in their fields.
“I am pleased and privileged to join the ranks of other esteemed academicians who have been similarly recognized,” said Dr. Feldman, during the Society’s formal induction ceremony held April 7th, in Baltimore, Maryland. As part of the ceremony, Dr. Feldman received an honorary medallion and certificate acknowledging his membership in the august Society.
Dr. Feldman served as a post-doctoral fellow in physiology at The Johns Hopkins University School of Medicine, then earned his medical degree from the Louisiana State University School of Medicine before returning to Hopkins where he served as an intern, resident and cardiology fellow. After Dr. Feldman joined the faculty in 1985, he was named director of the Heart Failure Research Program at Johns Hopkins.
Dr. Feldman remained at Johns Hopkins until 1994, when he joined the faculty at the University of Pittsburgh School of Medicine as the Harry S. Tack Professor of Medicine, Chief of the Division of Cardiology, and Director of the Cardiovascular Institute. In 2002, Dr. Feldman was named the Magee Professor of Medicine and Chairman of the Department of Medicine at Jefferson Medical College in Philadelphia. In September 2011, he was named Executive Dean of Temple University School of Medicine, and Chief Academic Officer of Temple University Health System.
A past president of the Association of Professors of Cardiology and the Heart Failure Society of America, Dr. Feldman recently received the Lifetime Achievement Award from the Heart Failure Society of America. During his time as president of the Heart Failure Society of America, he implemented Heart Failure Awareness week, which is currently recognized across both the United States and Europe.
Dr. Feldman is a renowned cardiovascular researcher who has led many clinical trials, and his work on the molecular biology of heart failure has been published in more than 250 peer-reviewed articles. He is the current and founding editor-in-chief of Clinical and Translational Science. He has received honors from the Association of University Cardiologists, the American Society for Clinical Investigation, the Association of American Physicians, Alpha Omega Alpha, and other organizations.
Dr. Feldman’s NIH-funded research has focused on the molecular pathobiology of heart failure. His lab was the first to recognize the role of G proteins, pro-inflammatory cytokines and vasopressin receptors in the development of the heart failure phenotype. Dr. Feldman has translated his basic science work to the clinical arena, chairing the steering committees of numerous multi-center clinical trials.
He recently published Pursuing Excellence in Healthcare: Preserving America’s Academic Medical Centers and Understanding Health Care Reform – Bridging the Gap between Myth and Reality, and is the editor of Heart Failure: Pharmacologic Management and Heart Failure: Device Management. He was a co-founder and member of the Board of Directors of Cardiokine, Inc., a biotechnology firm.